• Profile
Close

Once-weekly semaglutide in adults with overweight or obesity

New England Journal of Medicine Feb 15, 2021

Wilding JPH, Batterham RL, Calanna S, et al. - In adults with obesity, researchers performed this double-blind trial to ascertain if once-weekly semaglutide at a dose of 2.4 mg can reduce weight when taken as an adjunct to lifestyle intervention. A total of 1,961 adults with a body-mass index of 30 or greater (≥27 in persons with ≥1 weight-related coexisting condition), who did not have diabetes, were included. Participants were randomized, in a 2:1 ratio, to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention. Findings revealed that sustained, clinically relevant reduction in body weight was conferred by 2.4 mg of semaglutide once weekly plus lifestyle intervention in participants with overweight or obesity. The mean change in body weight from baseline to week 68 was −14.9% in the semaglutide group as compared with −2.4% with placebo.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay